• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Top 4 Health Care Stocks That Should Keep You Up At Night

    9/21/23 7:51:20 AM ET
    $CRNX
    $NXGN
    $OBIO
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology
    Get the next $CRNX alert in real time by email

    The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

    The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70.

    Here’s the latest list of major overbought players in this sector.

    Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO)

    • Orchestra BioMed was granted FDA approval of an investigational device exemption to initiate its global BACKBEAT study evaluating BackBeat CNT for hypertension in pacemaker patients. The company’s stock has a 52-week high of $23.39. .
    • RSI Value: 70.12
    • OBIO Price Action: Shares of Orchestra BioMed fell 10.2% to close at $9.67 on Wednesday.

    Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

    • Crinetics Pharmaceuticals priced its upsized $350 million public offering of 11,441,648 common shares at $30.59 per share. The company’s stock has a 52-week high of $31.00.
    • RSI Value: 72.20
    • CRNX Price Action: Shares of Crinetics Pharmaceuticals fell 2.6% to close at $28.62 on Wednesday.

    Takeda Pharmaceutical Company Limited (NYSE:TAK)

    • The FDA has accepted for review Takeda's new drug application resubmission for TAK-721 (budesonide oral suspension) for the short-term treatment of eosinophilic esophagitis. The company has a 52-week high of $17.15.
    • RSI Value: 73.80
    • TAK Price Action: Shares of Takeda Pharmaceutical fell 0.1% to close at $16.29 on Wednesday.

    NextGen Healthcare, Inc. (NASDAQ:NXGN)

    • NextGen Healthcare agreed to be acquired by Thoma Bravo for $23.95 per share in cash. The company’s 52-week high is $23.73.
    • RSI Value: 87.30
    • NXGN Price Action: Shares of NextGen Healthcare rose 0.1% to close at $23.67 on Wednesday.

     

    Read More: Over $18M Bet On Asana? Check Out These 3 Stocks Insiders Are Buying

    Get the next $CRNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRNX
    $NXGN
    $OBIO
    $TAK

    CompanyDatePrice TargetRatingAnalyst
    Takeda Pharmaceutical Company Limited
    $TAK
    1/13/2026Overweight
    Morgan Stanley
    Crinetics Pharmaceuticals Inc.
    $CRNX
    1/12/2026$67.00Neutral → Buy
    Goldman
    Orchestra BioMed Holdings Inc.
    $OBIO
    12/10/2025$15.00Buy
    TD Cowen
    Orchestra BioMed Holdings Inc.
    $OBIO
    8/20/2025Buy → Neutral
    BTIG Research
    Crinetics Pharmaceuticals Inc.
    $CRNX
    7/10/2025$36.00Neutral
    Goldman
    Takeda Pharmaceutical Company Limited
    $TAK
    4/2/2025Equal-Weight → Overweight
    Morgan Stanley
    Crinetics Pharmaceuticals Inc.
    $CRNX
    3/25/2025$60.00Buy
    Stifel
    Orchestra BioMed Holdings Inc.
    $OBIO
    3/20/2025$12.00Buy
    BTIG Research
    More analyst ratings

    $CRNX
    $NXGN
    $OBIO
    $TAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Takeda Pharma

    Morgan Stanley resumed coverage of Takeda Pharma with a rating of Overweight

    1/13/26 8:31:07 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals upgraded by Goldman with a new price target

    Goldman upgraded Crinetics Pharmaceuticals from Neutral to Buy and set a new price target of $67.00

    1/12/26 7:47:46 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Orchestra BioMed with a new price target

    TD Cowen initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $15.00

    12/10/25 8:29:27 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRNX
    $NXGN
    $OBIO
    $TAK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Hochman David P bought $20,350 worth of shares (5,000 units at $4.07), increasing direct ownership by 0.82% to 612,822 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    11/17/25 5:00:21 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Aryeh Jason bought $2,450 worth of shares (1,000 units at $2.45), increasing direct ownership by 0.93% to 108,482 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    9/19/25 6:57:57 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Fain Eric S bought $15,034 worth of shares (5,760 units at $2.61) (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    8/25/25 7:04:50 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRNX
    $NXGN
    $OBIO
    $TAK
    SEC Filings

    View All

    Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

    3/3/26 4:07:22 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Crinetics Pharmaceuticals Inc.

    144 - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    3/2/26 10:28:28 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

    6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

    3/2/26 6:04:16 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    $NXGN
    $OBIO
    $TAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT

    NEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced two presentations that will be given at the Technology Heart Failure and Therapeutics ("THT") and Cardiovascular Research Technologies ("CRT") 2026 Meetings highlighting the potential for the Company's Atrioventricular Interval Modulation Therapy ("AVIM Therapy") program in hypertensive heart disease and heart failure patients. Presentation at THT 2026Atrioventricular Interval Modulation

    3/3/26 8:00:00 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Alan Walshe Appointed General Manager of Takeda Canada

    A proven people‑focused commercial strategist with extensive global experience to lead Takeda Canada's next chapter of growth and impact.TORONTO, March 2, 2026  /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Alan Walshe as General Manager for Canada. Alan brings 17 years of experience with Takeda and its predecessor companies, most recently serving as Global Head of Commercial Strategy for the Plasma‑Derived Therapies Business Unit."Alan's depth of commercial expertise and global perspective, combined with his people‑focused leadership sty

    3/2/26 7:59:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

    Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal Study Submission Primarily Based on Phase 3 VERIFY Study, in Which Rusfertide Plus Standard of Care More Than Doubled Clinical Response Rates, as Well as Four-Year Efficacy and Safety Data from Phase 2 REVIVE/THRIVE Studies Prescription Drug User Fee Act (PDUFA) Target Action Date is in the Third Quarter of this Calendar Year Takeda ((TAK) and Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted

    3/2/26 2:00:00 AM ET
    $PTGX
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    $NXGN
    $OBIO
    $TAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Struthers Richard Scott was granted 62,000 shares, increasing direct ownership by 17% to 426,759 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    2/25/26 4:37:01 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Schilke Tobin was granted 32,000 shares, increasing direct ownership by 61% to 84,834 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    2/25/26 4:36:22 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Knight Jeff E. was granted 34,000 shares, increasing direct ownership by 39% to 121,929 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    2/25/26 4:34:51 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    $NXGN
    $OBIO
    $TAK
    Financials

    Live finance-specific insights

    View All

    Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead

    Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% at Actual Exchange Rates (AER); Impact of VYVANSE® Generics is Tapering Off Core Operating Profit Declined by 3.4% at both CER and AER Year to Date Reported Operating Profit Increased by 1.2% at AER Year to Date, Lower Restructuring Expenses More Than Offset Impairment   Takeda ((4502, NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The comp

    1/29/26 1:37:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 26 at 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 646-844-6383Access Code: 027322    Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection,

    1/26/26 5:00:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

    Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg) Achieved a 67% Mean Reduction in Androstenedione Levels While Simultaneously Enabling 88% of Participants Completing 12 Weeks of Treatment to Successfully Reduce Glucocorticoid Dose to Physiologic Replacement Levels Atumelnant's Favorable Benefit/Risk Profile Was Maintained in Cohort 4 and Open-Label Extension of Phase 2 CAH Study With No Hepatic Transaminase Adverse Events Management to Host Investor Conference Call Today at 8:30 AM ET SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cr

    1/5/26 8:00:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    $NXGN
    $OBIO
    $TAK
    Leadership Updates

    Live Leadership Updates

    View All

    Alan Walshe Appointed General Manager of Takeda Canada

    A proven people‑focused commercial strategist with extensive global experience to lead Takeda Canada's next chapter of growth and impact.TORONTO, March 2, 2026  /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Alan Walshe as General Manager for Canada. Alan brings 17 years of experience with Takeda and its predecessor companies, most recently serving as Global Head of Commercial Strategy for the Plasma‑Derived Therapies Business Unit."Alan's depth of commercial expertise and global perspective, combined with his people‑focused leadership sty

    3/2/26 7:59:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

    SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These appointments are expected to enhance the Company's operational, clinical, and regulatory capabilities as Oncolytics advances registration-directed development programs in pancreatic, colorectal, and anal cancers. Mr. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio. He br

    1/14/26 9:00:00 AM ET
    $CGON
    $ONCY
    $TAK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

    − Rhonda Pacheco to Succeed Julie Kim, Who Was Appointed to Be Takeda's Next CEO Takeda ((TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, effective September 29, as president of Takeda's U.S. Business Unit and will be a member of the Takeda Executive Team. Pacheco will succeed Julie Kim, who was appointed by the Takeda Board of Directors to succeed Christophe Weber as president and Chief Executive Officer (CEO) of Takeda in June 2026. With Pacheco's appointment, Kim will focus on preparing for the CEO transition, which includes serving as interim head of the Global Portfolio Division. This press r

    9/11/25 8:45:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    $NXGN
    $OBIO
    $TAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 7:55:29 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 5:46:54 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Crinetics Pharmaceuticals Inc.

    SC 13G - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 1:22:38 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care